A phase III study to access the safety and efficacy of prolgolimab 250 mg fixed dose administered every 3 weeks versus prolgolimab 1 mg/kg every 2 weeks in patients with metastatic melanoma (FLAT)

Lev Demidov, Galina Kharkevich, Natalia Petenko, Vladimir Moiseenko, Svetlana Protsenko, Tatiana Semiglazova, Anastasia Zimina, Nadezhda Kovalenko, Natalia Fadeeva, Dmitry Kirtbaya, Igor Belogortsev, Denis Tantsyrev, Svetlana Odintsova, Alfia Nesterova, Karina Vorontsova, Yulia Makarycheva, Yulia Linkova, Arina Zinkina-Orikhan, Anna Siliutina, Irina Sorokina, Daria Liaptseva, Vladimir Chistyakov, Anton Lutsky

Open source

DOI: 10.3389/fonc.2024.1385685
Published: 2024-09-04
Container: Frontiers in Oncology
Publisher: Frontiers Media SA
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fonc.2024.1385685,
  title = {A phase III study to access the safety and efficacy of prolgolimab 250 mg fixed dose administered every 3 weeks versus prolgolimab 1 mg/kg every 2 weeks in patients with metastatic melanoma (FLAT)},
  author = {Lev Demidov and Galina Kharkevich and Natalia Petenko and Vladimir Moiseenko and Svetlana Protsenko and Tatiana Semiglazova and Anastasia Zimina and Nadezhda Kovalenko and Natalia Fadeeva and Dmitry Kirtbaya and Igor Belogortsev and Denis Tantsyrev and Svetlana Odintsova and Alfia Nesterova and Karina Vorontsova and Yulia Makarycheva and Yulia Linkova and Arina Zinkina-Orikhan and Anna Siliutina and Irina Sorokina and Daria Liaptseva and Vladimir Chistyakov and Anton Lutsky},
  year = {2024},
  journal = {Frontiers in Oncology},
  doi = {10.3389/fonc.2024.1385685},
  url = {https://doi.org/10.3389/fonc.2024.1385685}
}

RIS

TY  - JOUR
TI  - A phase III study to access the safety and efficacy of prolgolimab 250 mg fixed dose administered every 3 weeks versus prolgolimab 1 mg/kg every 2 weeks in patients with metastatic melanoma (FLAT)
AU  - Lev Demidov
AU  - Galina Kharkevich
AU  - Natalia Petenko
AU  - Vladimir Moiseenko
AU  - Svetlana Protsenko
AU  - Tatiana Semiglazova
AU  - Anastasia Zimina
AU  - Nadezhda Kovalenko
AU  - Natalia Fadeeva
AU  - Dmitry Kirtbaya
AU  - Igor Belogortsev
AU  - Denis Tantsyrev
AU  - Svetlana Odintsova
AU  - Alfia Nesterova
AU  - Karina Vorontsova
AU  - Yulia Makarycheva
AU  - Yulia Linkova
AU  - Arina Zinkina-Orikhan
AU  - Anna Siliutina
AU  - Irina Sorokina
AU  - Daria Liaptseva
AU  - Vladimir Chistyakov
AU  - Anton Lutsky
PY  - 2024
JO  - Frontiers in Oncology
DO  - 10.3389/fonc.2024.1385685
UR  - https://doi.org/10.3389/fonc.2024.1385685
ER  -

APA

Demidov, L., Kharkevich, G., Petenko, N., Moiseenko, V., Protsenko, S., Semiglazova, T., Zimina, A., Kovalenko, N., Fadeeva, N., Kirtbaya, D., Belogortsev, I., Tantsyrev, D., Odintsova, S., Nesterova, A., Vorontsova, K., Makarycheva, Y., Linkova, Y., Zinkina-Orikhan, A., Siliutina, A., Sorokina, I., Liaptseva, D., Chistyakov, V., & Lutsky, A. (2024). A phase III study to access the safety and efficacy of prolgolimab 250 mg fixed dose administered every 3 weeks versus prolgolimab 1 mg/kg every 2 weeks in patients with metastatic melanoma (FLAT). Frontiers in Oncology. https://doi.org/10.3389/fonc.2024.1385685

Source records

crossref · retrieved 2026-09-26T20:03:56.240Z